William Blair Issues Pessimistic Estimate for SLP Earnings

Simulations Plus, Inc. (NASDAQ:SLP) – Research analysts at William Blair cut their Q3 2026 earnings per share estimates for shares of Simulations Plus in a research note issued on Monday, January 27th. William Blair analyst M. Smock now expects that the technology company will post earnings per share of $0.43 for the quarter, down from their prior estimate of $0.44. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Simulations Plus’ current full-year earnings is $1.09 per share.

SLP has been the subject of several other research reports. StockNews.com cut Simulations Plus from a “hold” rating to a “sell” rating in a report on Monday, November 4th. BTIG Research cut their target price on Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Stephens assumed coverage on shares of Simulations Plus in a research note on Friday, November 15th. They set an “overweight” rating and a $39.00 price target on the stock. Finally, KeyCorp increased their price objective on shares of Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Simulations Plus has a consensus rating of “Moderate Buy” and an average target price of $49.40.

Simulations Plus Stock Up 1.4 %

Shares of SLP stock opened at $34.27 on Thursday. Simulations Plus has a 12 month low of $24.00 and a 12 month high of $51.22. The firm has a market cap of $688.48 million, a PE ratio of 85.68 and a beta of 0.80. The stock has a 50 day moving average of $30.31 and a 200-day moving average of $32.70.

Institutional Investors Weigh In On Simulations Plus

Several large investors have recently bought and sold shares of the company. Barclays PLC raised its position in shares of Simulations Plus by 390.6% during the third quarter. Barclays PLC now owns 28,473 shares of the technology company’s stock worth $911,000 after purchasing an additional 22,669 shares during the period. Geode Capital Management LLC increased its stake in Simulations Plus by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock worth $14,367,000 after purchasing an additional 18,924 shares in the last quarter. State Street Corp raised its holdings in Simulations Plus by 4.7% during the 3rd quarter. State Street Corp now owns 640,303 shares of the technology company’s stock worth $20,503,000 after buying an additional 28,953 shares during the period. JPMorgan Chase & Co. lifted its stake in Simulations Plus by 106.0% in the third quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company’s stock valued at $1,517,000 after buying an additional 24,371 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Simulations Plus by 402.9% in the third quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company’s stock valued at $1,279,000 after buying an additional 32,002 shares during the period. Institutional investors own 78.08% of the company’s stock.

Insiders Place Their Bets

In other news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $31.76, for a total value of $635,200.00. Following the transaction, the director now directly owns 3,442,584 shares in the company, valued at $109,336,467.84. This trade represents a 0.58 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 19.40% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.